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Conventional antipsychotic medication is ineffective in around a third of patients with 
schizophrenia, and the nature of the therapeutic response is unpredictable. We 
investigated whether response to antipsychotics is related to brain glutamate levels 
prior to treatment. Proton magnetic resonance spectroscopy was used to measure 
glutamate levels (Glu/Cr) in the anterior cingulate cortex (ACC) and in the thalamus 
in antipsychotic-naïve or minimally-medicated patients with first episode psychosis 
(FEP, n = 71) and healthy volunteers (n = 60), at three sites. Following scanning, 
patients were treated with amisulpride for 4 weeks (n = 65), then 1H-MRS was 
repeated (n = 46). Remission status was defined in terms of Positive and Negative 
Syndrome Scale for Schizophrenia (PANSS) scores. Higher levels of Glu/Cr in the 
ACC were associated with more severe symptoms at presentation and a lower 
likelihood of being in remission at 4 weeks (P < 0.05). There were longitudinal 
reductions in Glu/Cr in both the ACC and thalamus over the treatment period (P < 
0.05), but these changes were not associated with the therapeutic response. There 
were no differences in baseline Glu/Cr between patients and controls. These results 
extend previous evidence linking higher levels of ACC glutamate with a poor 
antipsychotic response by showing that the association is evident before the initiation 








Treatment with conventional antipsychotic medications is ineffective in around a third 
of patients with schizophrenia.1 Non-response is associated with a sustained illness 
burden, and high health, personal and societal costs.2 Understanding the underlying 
biological mechanisms of therapeutic response is fundamental to the development of 
new treatments that may be useful when conventional medications are ineffective.  
 
Research using positron emission tomography indicates that psychosis is associated 
with elevated striatal dopamine function.5 However this is more evident among those 
patients who respond to antipsychotic treatment than in those who do not.3-6 
Schizophrenia has also been linked to hypofunction of N-methyl-D-aspartate 
(NMDA) glutamate receptors and increased frontal cortical glutamate release.7-9 Data 
from MR spectroscopy (1H-MRS) studies suggest that a poor antipsychotic response 
may be related to increased glutamate levels in the anterior cingulate cortex (ACC). 
This has been reported in patients who failed to achieve remission following a first 
episode of psychosis compared to those in remission,10 and in treatment-resistant 
patients with chronic schizophrenia relative to treatment-responsive patients.11, 12 
 
These 1H-MRS findings raise the possibility that higher ACC glutamate levels may 
predict a poor response to antipsychotics. However, because glutamate levels were 
measured in patients who had already been unwell for some time, it is possible that 
the findings were secondary to unremitted psychotic symptoms or to previous 
treatment. Some longitudinal 1H-MRS studies in schizophrenia have reported 
reductions in glutamatergic metabolites in the frontal cortex, thalamus, temporal 
cortex and striatum during antipsychotic treatment,13-16 but other studies have found 
no such changes.17-19 The mixed findings from these investigations may be related to 
the patient samples being small, clinically heterogeneous, and having been treated 
with a variety of different antipsychotics.20 In rodents, antipsychotic compounds can 
reduce NMDA antagonist-stimulated frontal glutamate levels, although this is not 
seen under all experimental conditions, 21-27 which may relate to the receptor 
pharmacology of the antipsychotic and the level of basal glutamatergic tone.   
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The primary aim of the present study was to examine whether response to 
antipsychotic medication is related to ACC glutamate levels prior to treatment, while 
minimizing the potentially confounding factors discussed above. We also examined 
the left thalamus, as glutamate metabolites in this region have been linked with 
clinical outcomes in individuals at clinical high risk of psychosis.28 The second 
objective was to test the hypothesis that antipsychotic treatment was associated with a 
longitudinal reduction in glutamate levels. Amisulpride was selected as the 
antipsychotic medication because it is relatively selective for D2/3 receptors, 29, 30 so 
any therapeutic response is attributable to dopamine D2/3 blockade. Furthermore, in a 
large trial of different antipsychotics in first episode patients, amisulpride was 
associated with a high rate of symptomatic remission (approximately 40% after 4 




This study was conducted as part of the Optimisation of Treatment and Management 
of Schizophrenia in Europe (OPTiMiSE) clinical trial (www.optimisetrial.eu; 
EudraCT-Number: 2010-020185-19; clinicaltrials.gov identifier: NCT01248195). 
Participants in the 1H-MRS substudy were assessed at three study sites (King’s 
College London, UK; University Medical Centre Utrecht, The Netherlands; Mental 
Health Centre, Glostrup, Denmark). All sites had local ethical and regulatory 




Inclusion required that patients were within the first two years of onset of the first 
psychotic episode, with previous antipsychotic exposure of less than 15 days in the 
last year. There was no wash-out period before baseline imaging.  Inclusion also 
required that participants were 18 to 40 years old, and had a diagnosis of 
schizophrenia, schizophreniform or schizoaffective disorder, as defined by DSM-IV 
criteria in conjunction with the Mini International Neuropsychiatric Interview.32 
Female participants were required to be using a reliable method of contraception. 
Exclusion criteria included contraindications to the study medications or to MRI 
scanning, pregnancy, undergoing compulsory treatment or being under legal custody, 
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or being unable to provide written informed consent. Healthy volunteers (n = 60) 
were 18-40 years old, and had no history of psychiatric illness or MRI 
contraindications.  
 
Assessment and antipsychotic treatment schedule 
 
In the patient group, symptoms and level of functioning were assessed at baseline and 
4 weeks using the Positive and Negative Syndrome Scale for Schizophrenia 
(PANSS)33 and Personal and Social Performance (PSP) scale34 respectively. The 
PANSS inter-rater reliability score was 0.82 (Supplementary Methods). Illicit 
substance use was determined by self-report.  
 
After baseline 1H-MRS, patients received open-label amisulpride, with individual 
dosing between 200-800mg, as determined by the clinical judgement of the treating 
physician, and to a target dose of 400mg/day based on the EUFEST study.31  The 4-
week period corresponds to the period over which the greatest degree of symptomatic 
improvement is observed.35, 36 The protocol prohibited the use of other antipsychotics, 
but other classes of concomitant medication were permitted and recorded. PANSS 
scores after amisulpride administration were used to determine whether or not patients 
had reached symptomatic remission, defined according to the criteria of Andreasen,37 
with exclusion of the 6-month observation period (Supplementary Methods). At the 




1H-MRS data were acquired at 3 Tesla. There was no restriction on the time of day for 
scanning, or for matching the time of day for baseline and follow-up scan acquisition.  
1H-MRS voxels were positioned in the ACC (20 x 20 x 20mm) and in the left 
thalamus (15 right-left x 20 x 20mm) (Supplementary Figure 1). Spectra were 
acquired using Point RESolved Spectroscopy (TE = 30msec; TR  = 3000msec; 96 
averages). Spectra were analyzed using LC Model version 6.3-1L.38 The predefined 
primary measure was total voxel glutamate scaled to creatine (Glu/Cr). Voxel tissue 
content was extracted using Gannet 2.0 (http://www.gabamrs.com/). A detailed 
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description of the multisite MRI data acquisition and quality control is provided in the 




Binary logistic regression determined the association between Glu/Cr and outcome 
(Remission versus Non-Remission). Linear regression examined relationships 
between Glu/Cr and symptom scores, where the minimum possible PANSS scores 
were subtracted when calculating the PANSS percentage change.39 1H-MRS 
metabolite estimates were group-mean centred by site for the regression models. 
Repeated measures general linear model examined the effect of amisulpride 
administration and remission status on voxel Glu/Cr levels. Between-group 
comparisons of Glu/Cr levels were performed using univariate ANOVA, including 
site as a fixed factor. All analyses were performed in SPSS (version 23, IBM), with a 






Seventy-two patients completed baseline 1H-MRS acquisition. One patient was 
excluded from all analyses due to a protocol violation (previous antipsychotic 
medication lasting >15 days). Forty-five (63%) patients were antipsychotic-naïve; the 
remaining 26 had received antipsychotics for a median of 9 days in the period 
immediately prior to inclusion (Table 1).  
 
After scanning, 65 patients were treated with amisulpride (duration of treatment 30.6 
± 7.6 days), while 6 withdrew from the study. The amisulpride dose at the end of 
treatment was 347.7 ± 138.2 mg/day. At this point, 41 patients (63%) met remission 
criteria and 24 (37%) did not. Compared to the Remission group, the Non-Remission 
group was younger, more symptomatic at baseline, and was taking higher doses of 
amisulpride at the end of treatment (Table 1). 
 
1H-MRS data quality 
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Glu/Cr values in patients were normally distributed (ACC: df = 70; Shapiro-Wilk = 
0.98; P = 0.22; Thalamus: df = 62; Shapiro-Wilk = 0.98; P = 0.51). Spectral quality 
measures are available in Supplementary Tables 1 and 2. Data failing quality control 
were excluded from analyses. Spectral quality did not differ between the Remission 
and Non-Remission patient groups and there were no significant group differences in 
voxel tissue content. Site effects were apparent across several variables 
(Supplementary Tables 1 and 2).  
 
Baseline glutamate levels and prediction of remission  
 
Baseline ACC Glu/Cr was associated with the likelihood of remission following 
treatment (χ2 = 4.61; P = 0.03, Nagelkerke r2 = 0.10; B = 3.63; SE = 1.76; Wald = 
4.25; P = 0.04; Exp(B) = 37.88), The regression model correctly classified 69% of 
cases (90% Remitters and 30% Non-Remitters). Due to baseline group differences, 
age and PANSS total score were subsequently added to the regression model. This 
increased the predictive accuracy to 75% (85% Remitters, 57% Non-Remitters) (χ2 = 
15.64; P = 0.001, Nagelkerke r2 = 0.30). Secondary analyses including only 
antipsychotic-naïve patients also found that ACC Glu/Cr levels predicted remission 
status (χ2 = 4.73; P = 0.03, Nagelkerke r2 = 0.15; 66% overall accuracy). Glu/Cr in the 
thalamus at baseline was not associated with remission status (χ2 = 0.09; P = 0.76, 
Nagelkerke r2 = 0.002). None of the other metabolites in either the ACC or thalamus 
at baseline, including creatine, were associated with remission status (Supplement 
Table 2).  
 
In the ACC, Glu/Cr was significantly higher in the Non-Remission than Remission 
group (F1,63 = 5.99; P = 0.02; ηp2 = 0.09; Table 2; Figure 1). This difference remained 
significant when only antipsychotic-naïve patients were included in the analysis (F1,41 
= 5.21; P = 0.03), and when the number of days to follow-up was covaried for (F1,61 = 
4.63; P = 0.04).  
 
Relationships between glutamate levels and clinical measures  
 
At baseline, higher levels of ACC Glu/Cr were associated with greater severity of 
overall symptomatology (PANSS total: n = 69; r2 = 0.08; β = 0.28; t = 2.38; P = 0.02; 
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PANSS general: n = 69; r2 = 0.09; β = 0.31; t = 2.66; P = 0.01, Figure 2) and lower 
level of functioning (PSP: n = 63; r2 = 0.12; β = -0.34; t = -2.84; P = 0.006; 
Supplement Figure 2). These findings were not significant when limited to 
antipsychotic-naïve patients. Similar relationships were evident between baseline 
ACC Glu/Cr and symptom severity (PANSS total: n = 65; r2 = 0.09; β = 0.30; t = 
2.49; P = 0.02; PANSS positive: n = 65; r2 = 0.09; β = 0.30; t = 2.46; P = 0.02; 
PANSS general: n = 65; r2 = 0.07; β = 0.27; t = 2.20; P = 0.03, Figure 2) and 
functioning (PSP: n = 54; r2 = 0.20; β = -0.44; t = -3.58; P < 0.001, Supplement 
Figure 2) at 4 weeks across the whole sample, and in only patients who were 
antipsychotic-naïve at baseline (PANSS positive: n = 39; r2 = 0.16; P = 0.01; PSP: n = 
36; r2 = 0.15; P = 0.02). There were no significant associations between baseline ACC 
Glu/Cr and the subsequent longitudinal percentage change in PANSS or PSP scores in 
the whole sample (P > 0.05), but when analysis was restricted to antipsychotic-naïve 
patients, baseline ACC Glu/Cr correlated with percentage reduction in total PANSS 
score (n = 39; r2 = 0.13; β = -0.36; t = -2.31; P = 0.03, Supplement Figure 3).  
 
In the thalamus, baseline Glu/Cr was not significantly associated with symptom 
severity or functioning, at either baseline or follow-up (P > 0.05). Baseline Glu/Cr in 
the thalamus was associated with the longitudinal percentage change in both the 
PANSS total (n = 65; r2 = 0.09; β = -0.30; t = -2.34; P = 0.02) and the PANSS general 
(n = 65; r2 = 0.08; β = -0.29; t = -2.19; P = 0.03) score over the treatment period 
(Supplement Figure 4). However no significant relationships were detected in only 
the antipsychotic-naïve subsample.  
 
Effect of amisulpride on glutamate levels 
 
Forty-six patients completed 1H-MRS at 4 weeks (33 ± 5 days). In the ACC, Glu/Cr 
levels were significantly lower at 4 weeks than at baseline in both the total patient 
sample (Table 2; Figure 4; main effect of time: F1,44 = 5.67; P = 0.02; ηp2 = 0.11; 
mean reduction = 3.6%), and in the antipsychotic-naïve subgroup (F1,29 = 6.68; P = 
0.02). ACC Glu/Cr was lower over both time-points in the remission group (n = 13; 
F1,44 = 6.22; P = 0.02). The time*remission status interaction was non-significant.  
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In the thalamus, Glu/Cr was also lower at follow-up than at baseline (Table 2; Figure 
4; main effect of time: F1,35 = 4.68; P = 0.04; ηp2 = 0.12; mean reduction = 2.6%), 
but the main effect of remission status and the time*remission status interaction were 
non-significant. The effect of time was not significant in only antipsychotic-naïve 
patients.  
 
In both the ACC and the thalamus, the longitudinal percentage change in Glu/Cr was 
not significantly associated with the percentage change in symptom severity over the 
treatment period, or with amisulpride end dose.  
 
Glutamate levels in patients compared to healthy volunteers 
 
Compared to the patient group, the healthy volunteer group did not differ in gender (P 
= 0.83), but were older (26.8 ± 5.4 vs. 24.7 ± 5.4 years, T(129) = 2.41; P = 0.02). 
There were no significant differences in Glu/Cr in the ACC or thalamus, or in any 
other metabolite, in patients compared to healthy volunteers (P > 0.05, Supplement 
Table 2), including when age was included in the model, or when analysis was 
restricted to antipsychotic-naïve patients. In healthy volunteers, neither Glu/Cr in the 
ACC nor thalamus changed significantly over time (Supplement Table 2; ACC: F1,38 





We used 1H-MRS to examine the relationship between ACC glutamate levels and the 
response to amisulpride in antipsychotic-naïve or minimally-medicated patients with 
first episode psychosis. As hypothesised, we found that higher pre-treatment levels of 
Glu/Cr in the ACC were associated with a lower likelihood of symptomatic remission.  
 
An association between higher ACC Glu/Cr levels and poor response to treatment is 
consistent with data from previous cross-sectional studies in patients who had already 
been treated with antipsychotic medication. These also reported that non-responders 
had higher ACC glutamate levels than responders.10, 11 Our findings are also in line 
with data from a prospective study in chronic schizophrenia which indicated that 
patients with higher frontal Glx (glutamate plus glutamine) levels were more likely to 
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show a poor response to a subsequent switch in antipsychotic medication.40 The 
present study extends these findings by providing the first evidence that the 
association between ACC glutamate levels and antipsychotic response is present at 
the onset of psychosis and predates antipsychotic treatment. Thus, it does not appear 
to be an effect of chronic illness or of antipsychotic medication.  
 
Although we analysed the data in terms of categorical treatment outcomes 
(remission/non-remission), across the total patient sample the distribution of ACC 
Glu/Cr levels was normal (unimodal). This suggests that the relationship between 
glutamate levels and treatment response in psychosis may be a graded, as opposed to 
a categorical one. Indeed, a continuous relationship was evident when we examined 
the association between ACC Glu/Cr levels and clinical measures;  at both baseline 
and after treatment, ACC Glu/Cr was positively correlated with symptom severity and 
negatively correlated with level of functioning. In patients with first episode 
psychosis, greater illness severity and a low level of functioning are associated with 
relatively poor clinical outcomes.41, 42 While these clinical measures and brain 
glutamate levels might be related to outcomes via distinct mechanisms, a more 
parsimonious interpretation is that illness severity, a low level of functioning and a 
poor response to treatment are all manifestations of central glutamate dysfunction.  
 
Although currently available antipsychotics vary in their affinity for different receptor 
subtypes, antagonism at D2/3 dopamine receptors is fundamental to their therapeutic 
effect.43 Studies using PET and SPECT suggest that striatal dopamine dysfunction is 
more markedly elevated in patients who respond to antipsychotic treatment than in 
poor responders.4, 5 6 Independent work suggests that there are differences in 
functional connectivity between the striatum and the ACC in responders and non-
responders,44 and that the strength of functional and structural connectivity between 
striatal and medial frontal regions (including the ACC) changes in association with an 
antipsychotic response.45-49  Our findings add to this literature by raising the 
possibility that these differences in connectivity may be related to glutamate function 
in the ACC. This hypothesis could be tested by combining 1H-MRS glutamate 
imaging with measures of functional connectivity in patients studied over the course 
of antipsychotic treatment.  
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Our second major finding was that 4 weeks of amisulpride was associated with small 
(~3%) but significant reductions in glutamate in both the ACC and the thalamus, 
independent of the therapeutic response. These observations are in line with previous 
1H-MRS studies, which have reported longitudinal reductions in glutamatergic 
metabolites in the frontal cortex, thalamus, temporal cortex and striatum during 
antipsychotic treatment,13-16 although not all have found significant changes.17-19 They 
are also consistent with evidence that medial frontal Glx is higher in non-medicated 
than in medicated patients.50 The lack of significant relationship between reductions 
in glutamate and reductions in symptoms over amisulpride treatment is consistent 
with most14, 15, 17, 19 but not all16, 51 previous studies. Although higher glutamate levels 
at baseline are associated with higher symptoms severity and a poor antipsychotic 
response, the small reductions in glutamate that occur with antipsychotic treatment 
may not translate into symptomatic improvement. Nevertheless, as antipsychotics can 
alter brain glutamate levels, medication status and treatment history need to be clearly 
defined in 1H-MRS studies in psychosis.  
 
As amisulpride has relatively selective affinity for D2/3 dopamine receptors,29, 30 we 
attribute the longitudinal changes in Glu/Cr following treatment with amisulpride to 
an effect of D2/3 blockade. This is consistent with data from preclinical models of 
psychosis, in which the administration of antipsychotics, including D2/3-selective 
compounds, leads to decreases in stimulated glutamate efflux22, 24, 52 and 
glutamatergic pyramidal neuron activity.53 This may occur because D2/3 antagonists 
block the dopaminergic inhibition of a subpopulation of cortical GABAergic neurons, 
increasing their inhibition of glutamatergic pyramidal neurons and decreasing 
glutamatergic activity.54, 55  
 
There was no significant difference in glutamate levels between patients and healthy 
volunteers in either the ACC or the thalamus. This is consistent with the majority of 
findings from previous 1H-MRS studies in minimally-medicated or antipsychotic-
naïve first episode patients14, 18, 56-60 and a recent meta-analysis61 although one study 
has reported greater ACC glutamate in patients than controls.62 Glutamine and the 
glutamine/glutamate ratio may be elevated in first episode psychosis,18, 57, 58 but we 
were unable to evaluate this as our acquisition parameters at 3 Tesla did not allow 
reliable quantification of glutamine.  
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Strengths of the present study include the use of antipsychotic-naïve or minimally-
medicated patients with first episode psychosis, which increased the clinical 
homogeneity of the sample and minimized the potentially confounding effects of 
chronic illness and previous treatment. The standardisation of their subsequent 
treatment with a single, D2/3-selective antipsychotic reduced the variance that could 
have resulted from using multiple different antipsychotic drugs, and allowed 
interpretation of the findings in terms of D2/3 antagonism. A further strength was the 
relatively large sample size compared to previous 1H-MRS studies of the effects of 
antipsychotic treatment (see Egerton et al.,20), achieved using a multi-centre design. 
To our knowledge, this is the first published multi-centre 1H-MRS study in 
schizophrenia.  
 
This study also had limitations. Multi-centre 1H-MRS including MRI platforms from 
different manufacturers is not without additional technical challenges. For example, 
site effects were present throughout the study data, which may have decreased 
statistical power. These issues will be discussed in detail in a subsequent article 
focussing on multicentre 1H-MRS methodology. The use of creatine-scaled values 
means that results may be influenced by differences or changes in voxel creatine 
levels. One study reported that creatine levels are altered in schizophrenia,63 but no 
overall differences in creatine levels are reported in either meta-analysis,64 or in the 
largest 1H-MRS study in schizophrenia to date.65 The glutamate measurements 
available from 1H-MRS reflect the mean concentration of glutamate in a relatively 
large voxel, and it is not possible to specifically attribute findings to glutamatergic 
neurotransmission, or to glutamate levels in a particular cell type.66 As the study 
required that patients were willing to participate in a clinical trial involving serial 
psychopathological assessments and neuroimaging sessions, and excluded patients 
receiving compulsory treatment, the sample may have included patients who were 
less severely unwell than in the general first episode population. Our analysis did not 
assess the possible influence of illicit substance use, concomitant medication or the 
time of day on 1H-MRS measures, and, in patients who were not antipsychotic-naïve, 
there was no washout period before the baseline scan. Finally, the participants met a 
number of DSM-IV schizophrenia diagnostic subcategories, which may have 
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increased between-subject variability. However whether glutamatergic function varies 
across schizophrenia diagnostic subgroups is unknown.  
  
The finding that high levels of ACC glutamate were associated with a poor response 
to antipsychotic treatment raises the question of whether 1H-MRS glutamate 
measurements could be used to help predict treatment outcomes. The overall level of 
accuracy in predicting remission at 4 weeks was 69%, which increased to 75% when 
PANSS total score and age were included in the model. This is not sufficient for 
clinical decision-making or clinical trial stratification. Predictive accuracy may be 
improved by combining 1H-MRS measurements with other biomarkers associated 
with antipsychotic response,67 such as striatal dopamine function,4, 5 functional 




This work was funded by a grant from the European Commission within the 7th 
Program (HEALTH-F2-2010-242114). We would like to thank the other OPTiMiSE 
investigators for their on-going support during the study. Dr Egerton received 
additional support from the Brain and Behaviour Research Foundation (YIA 2012–
18777). Research at the London site was supported by the Department of Health via 
the National Institute for Health Research (NIHR) Specialist Biomedical Research 
Center for Mental Health award to South London and Maudsley NHS Foundation 
Trust (SLaM) and the Institute of Psychiatry at King's College London, London. The 
views expressed are those of the authors and not necessarily those of the NHS, the 
NIHR, or the Department of Health. 
 
Conflict of Interest 
GJB received honoraria for teaching from General Electric Healthcare during the 
course of this study, and acts as a consultant for IXICO. AE has received research 
funding from Roche and consultancy payment from Heptares Therapeutics. BG is the 
leader of a Lundbeck Foundation Center of Excellence for Clinical Intervention and 
Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an 
independent grant from the Lundbeck Foundation based on international review and 
partially financed by the Mental Health Services in the Capital Region of Denmark, 
 14
the University of Copenhagen, and other foundations. PM has received consultancy 
payment for Sunovion and Takeda. RPI has received honoraria as a speaker for 
Lundbeck. JMS has received honoraria from Roche and Janssen and consultancy 








1. Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. 
CurrMedResOpin 1997; 14(1): 1-20. 
 
2. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. 
Schizophr Bull 2004; 30(2): 279-293. 
 
3. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. 
The Nature of Dopamine Dysfunction in Schizophrenia and What This Means 
for Treatment: Meta-analysis of Imaging Studies. ArchGenPsychiatry 2012; 
69(8): 776-786. 
 
4. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et 
al. Increased baseline occupancy of D2 receptors by dopamine in 
schizophrenia. ProcNatlAcadSciUSA 2000; 97(14): 8104-8109. 
 
5. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine 
Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia. 
AmJPsychiatry 2012; 169(11): 1203-1210. 
 
6. Wulff S, Pinborg LH, Svarer C, Jensen LT, Nielsen MO, Allerup P et al. 
Striatal D(2/3) Binding Potential Values in Drug-Naive First-Episode 
Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull 
2015; 41(5): 1143-1152. 
 
7. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of 
schizophrenia. AmJPsychiatry 1991; 148(10). 
 
8. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic 
neurotransmission by ketamine: a novel step in the pathway from NMDA 
receptor blockade to dopaminergic and cognitive disruptions associated with 
the prefrontal cortex. JNeurosci 1997; 17(8). 
 
9. Moghaddam B, Krystal JH. Capturing the angel in "angel dust": twenty years 
of translational neuroscience studies of NMDA receptor antagonists in animals 
and humans. Schizophr Bull 2012; 38(5): 942-949. 
 
10. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK et al. 
Anterior cingulate glutamate levels related to clinical status following 
treatment in first-episode schizophrenia. Neuropsychopharmacology 2012; 
37(11): 2515-2521. 
 
11. Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N et 
al. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior 
Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophr 
Bull 2016; 42(3): 744-752. 
 
 16
12. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM et al. 
Antipsychotic Treatment Resistance in Schizophrenia Associated with 
Elevated Glutamate Levels but Normal Dopamine Function. Biol Psychiatry 
2013. 
 
13. Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW et 
al. Grey matter and social functioning correlates of glutamatergic metabolite 
loss in schizophrenia. Br J Psychiatry 2011; 198(6): 448-456. 
 
14. Goto N, Yoshimura R, Kakeda S, Nishimura J, Moriya J, Hayashi K et al. Six-
month treatment with atypical antipsychotic drugs decreased frontal-lobe 
levels of glutamate plus glutamine in early-stage first-episode schizophrenia. 
Neuropsychiatric disease and treatment 2012; 8: 119-122. 
 
15. Szulc A, Galinska B, Tarasow E, Waszkiewicz N, Konarzewska B, Poplawska 
R et al. Proton magnetic resonance spectroscopy study of brain metabolite 
changes after antipsychotic treatment. Pharmacopsychiatry 2011; 44(4): 148-
157. 
 
16. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Stephano S, Favila R, 
Diaz-Galvis L et al. Glutamate levels in the associative striatum before and 
after 4 weeks of antipsychotic treatment in first-episode psychosis: a 
longitudinal proton magnetic resonance spectroscopy study. JAMA psychiatry 
2013; 70(10): 1057-1066. 
 
17. Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B et al. 
The effect of risperidone on metabolite measures in the frontal lobe, temporal 
lobe, and thalamus in schizophrenic patients. A proton magnetic resonance 
spectroscopy (1H MRS). Pharmacopsychiatry 2005; 38(5). 
 
18. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C et al. (1)H-
MRS at 4 Tesla in minimally treated early schizophrenia. MolPsychiatry 
2010: 629-636. 
 
19. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE et al. Modulation 
of brain and serum glutamatergic concentrations following a switch from 
conventional neuroleptics to olanzapine. BiolPsychiatry 2002; 51(6). 
 
20. Egerton A, Bhachu A, Merritt K, McQueen G, Szulc A, McGuire P. Effects of 
Antipsychotic Administration on Brain Glutamate in Schizophrenia: A 
Systematic Review of Longitudinal 1H-MRS Studies. Frontiers in psychiatry 
2017; 8: 66. 
 
21. Carli M, Calcagno E, Mainolfi P, Mainini E, Invernizzi RW. Effects of 
aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of 
schizophrenia in rats: relationship with glutamate release in the medial 
prefrontal cortex. Psychopharmacology (Berl) 2011; 214(3): 639-652. 
 
 17
22. Abekawa T, Ito K, Nakagawa S, Nakato Y, Koyama T. Effects of aripiprazole 
and haloperidol on progression to schizophrenia-like behavioural 
abnormalities and apoptosis in rodents. Schizophr Res 2011; 125(1): 77-87. 
 
23. Lopez-Gil X, Babot Z, Amargos-Bosch M, Sunol C, Artigas F, Adell A. 
Clozapine and haloperidol differently suppress the MK-801-increased 
glutamatergic and serotonergic transmission in the medial prefrontal cortex of 
the rat. Neuropsychopharmacology 2007; 32(10): 2087-2097. 
 
24. Lopez-Gil X, Artigas F, Adell A. Role of different monoamine receptors 
controlling MK-801-induced release of serotonin and glutamate in the medial 
prefrontal cortex: relevance for antipsychotic action. The international journal 
of neuropsychopharmacology 2009; 12(4): 487-499. 
 
25. Roenker NL, Gudelsky G, Ahlbrand R, Bronson SL, Kern JR, Waterman H et 
al. Effect of paliperidone and risperidone on extracellular glutamate in the 
prefrontal cortex of rats exposed to prenatal immune activation or MK-801. 
Neurosci Lett 2011; 500(3): 167-171. 
 
26. McLoughlin GA, Ma D, Tsang TM, Jones DN, Cilia J, Hill MD et al. 
Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain 
using 1H NMR spectroscopy. JProteomeRes 2009; 8(4): 1943-1952. 
 
27. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ et al. 
Long-term treatment of rats with haloperidol: lack of an effect on brain N-
acetyl aspartate levels. Neuropsychopharmacology 2006; 31(4). 
 
28. Egerton A, Stone JM, Chaddock CA, Barker GJ, Bonoldi I, Howard RM et al. 
Relationship between brain glutamate levels and clinical outcome in 
individuals at ultra high risk of psychosis. Neuropsychopharmacology 2014; 
39(12): 2891-2899. 
 
29. Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD. Comparison of 
the in-vitro receptor selectivity of substituted benzamide drugs for brain 
neurotransmitter receptors. The Journal of pharmacy and pharmacology 1988; 
40(6): 415-421. 
 
30. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al. 
Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 
receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol 
Exp Ther 1997; 280(1): 83-97. 
 
31. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP et 
al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and 
schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 
371(9618): 1085-1097. 
 
32. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. 
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the 
 18
development and validation of a structured diagnostic psychiatric interview for 
DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 Suppl 20: 22-33;quiz 34-57. 
 
33. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale 
(PANSS) for schizophrenia. SchizophrBull 1987; 13(2): 261-276. 
 
34. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, 
reliability and acceptability of a new version of the DSM-IV Social and 
Occupational Functioning Assessment Scale (SOFAS) to assess routine social 
functioning. Acta PsychiatrScand 2000; 101(4): 323-329. 
 
35. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of 
antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 
2003; 60(12): 1228-1235. 
 
36. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis 
of antipsychotic drug action: a hypothesis tested, confirmed and extended. 
Biol Psychiatry 2005; 57(12): 1543-1549. 
 
37. Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, 
Weinberger DR. Remission in schizophrenia: proposed criteria and rationale 
for consensus. Am J Psychiatry 2005; 162(3): 441-449. 
 
38. Provencher SW. Estimation of metabolite concentrations from localized in 
vivo proton NMR spectra. Magn ResonMed 1993; 30(6): 672-679. 
 
39. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' 
in antipsychotic drug trials: recommendations for the use of scale-derived 
cutoffs. Neuropsychopharmacology 2007; 32(9): 1903-1910. 
 
40. Szulc A, Konarzewska B, Galinska-Skok B, Lazarczyk J, Waszkiewicz N, 
Tarasow E et al. Proton magnetic resonance spectroscopy measures related to 
short-term symptomatic outcome in chronic schizophrenia. Neurosci Lett 
2013; 547: 37-41. 
 
41. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B et al. 
Predictors of treatment response from a first episode of schizophrenia or 
schizoaffective disorder. Am J Psychiatry 1999; 156(4): 544-549. 
 
42. Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD et al. 
Antipsychotic treatment resistance in first-episode psychosis: prevalence, 
subtypes and predictors. Psychol Med 2017: 1-9. 
 
43. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for 
dopamine D2 receptors. Progress in neuro-psychopharmacology & biological 
psychiatry 2003; 27(7). 
 
44. Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt KH, John M et 
al. Baseline Striatal Functional Connectivity as a Predictor of Response to 
Antipsychotic Drug Treatment. Am J Psychiatry 2016; 173(1): 69-77. 
 19
 
45. Lui S, Li T, Deng W, Jiang L, Wu Q, Tang H et al. Short-term effects of 
antipsychotic treatment on cerebral function in drug-naive first-episode 
schizophrenia revealed by "resting state" functional magnetic resonance 
imaging. Arch Gen Psychiatry 2010; 67(8): 783-792. 
 
46. Bolding MS, White DM, Hadley JA, Weiler M, Holcomb HH, Lahti AC. 
Antipsychotic Drugs Alter Functional Connectivity between the Medial 
Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by 
H215O PET. Frontiers in psychiatry 2012; 3: 105. 
 
47. Reis Marques T, Taylor H, Chaddock C, Dell'acqua F, Handley R, Reinders 
AA et al. White matter integrity as a predictor of response to treatment in first 
episode psychosis. Brain 2014; 137(Pt 1): 172-182. 
 
48. Ebdrup BH, Raghava JM, Nielsen MO, Rostrup E, Glenthoj B. Frontal 
fasciculi and psychotic symptoms in antipsychotic-naive patients with 
schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor 
blockade. J Psychiatry Neurosci 2016; 41(2): 133-141. 
 
49. Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K et al. 
Antipsychotic treatment and functional connectivity of the striatum in first-
episode schizophrenia. JAMA psychiatry 2015; 72(1): 5-13. 
 
50. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X et al. Elevated 
prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in 
schizophrenia measured in vivo with proton magnetic resonance spectroscopy. 
ArchGenPsychiatry 2012; 69(5): 449-459. 
 
51. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of 
metabolic changes in chronic schizophrenia after neuroleptic treatment by in 
vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 1996; 31(6). 
 
52. Abekawa T, Ito K, Koyama T. Role of the simultaneous enhancement of 
NMDA and dopamine D1 receptor-mediated neurotransmission in the effects 
of clozapine on phencyclidine-induced acute increases in glutamate levels in 
the rat medial prefrontal cortex. Naunyn Schmiedebergs ArchPharmacol 2006; 
374(3): 177-193. 
 
53. Homayoun H, Moghaddam B. Fine-tuning of awake prefrontal cortex neurons 
by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol 
Psychiatry 2007; 61(5): 679-687. 
 
54. Gao WJ, Wang Y, Goldman-Rakic PS. Dopamine modulation of perisomatic 
and peridendritic inhibition in prefrontal cortex. J Neurosci 2003; 23(5): 1622-
1630. 
 
55. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine 
modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. 
J Neurosci 2001; 21(10): 3628-3638. 
 20
 
56. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L et al. 
Measurement of glutamate and glutamine in the medial prefrontal cortex of 
never-treated schizophrenic patients and healthy controls by proton magnetic 
resonance spectroscopy. ArchGenPsychiatry 1997; 54(10). 
 
57. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al. 
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated 
patients with schizophrenia and healthy volunteers. AmJPsychiatry 2002; 
159(11): 1944-1946. 
 
58. Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK 
et al. Longitudinal grey-matter and glutamatergic losses in first-episode 
schizophrenia. BrJPsychiatry 2007; 191: 325-334. 
 
59. Galinska B, Szulc A, Tarasow E, Kubas B, Dzienis W, Czernikiewicz A et al. 
Duration of untreated psychosis and proton magnetic resonance spectroscopy 
(1H-MRS) findings in first-episode schizophrenia. MedSci Monit 2009; 15(2). 
 
60. Natsubori T, Inoue H, Abe O, Takano Y, Iwashiro N, Aoki Y et al. Reduced 
frontal glutamate + glutamine and N-acetylaspartate levels in patients with 
chronic schizophrenia but not in those at clinical high risk for psychosis or 
with first-episode schizophrenia. Schizophr Bull 2014; 40(5): 1128-1139. 
 
61. Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of 
Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic 
Resonance Spectroscopy Studies. JAMA psychiatry 2016; 73(7): 665-674. 
 
62. Kim SY, Kaufman MJ, Cohen BM, Jensen JE, Coyle JT, Du F et al. In Vivo 
Brain Glycine and Glutamate Concentrations in Patients With First-Episode 
Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance 
Spectroscopy at 4T. Biol Psychiatry 2017. 
 
63. Ongur D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine 
abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 2009; 
172(1): 44-48. 
 
64. Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D et al. 
Neurometabolites in schizophrenia and bipolar disorder - a systematic review 
and meta-analysis. Psychiatry Res 2012; 203(2-3): 111-125. 
 
65. Bustillo JR, Jones T, Chen H, Lemke N, Abbott C, Qualls C et al. 
Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A 
Spectroscopic Imaging Study in a Large Schizophrenia Sample. Schizophr 
Bull 2017; 43(3): 611-619. 
 
66. Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of 
neurotransmitters and modulators with magnetic resonance spectroscopy: 
application to schizophrenia. Neurosci Biobehav Rev 2015; 51: 276-295. 
 
 21
67. McGuire P, Dazzan P. Does neuroimaging have a role in predicting outcomes 
in psychosis? World Psychiatry 2017; 16(2): 209-210. 
 
68. Stevenson JM, Reilly JL, Harris MS, Patel SR, Weiden PJ, Prasad KM et al. 
Antipsychotic pharmacogenomics in first episode psychosis: a role for 
glutamate genes. Translational psychiatry 2016; 6: e739. 
 
69. Bishop JR, Ellingrod VL, Moline J, Miller D. Association between the 
polymorphic GRM3 gene and negative symptom improvement during 
olanzapine treatment. Schizophr Res 2005; 77(2-3): 253-260. 
 
70. Bishop JR, Miller del D, Ellingrod VL, Holman T. Association between type-
three metabotropic glutamate receptor gene (GRM3) variants and symptom 
presentation in treatment refractory schizophrenia. Human 
psychopharmacology 2011; 26(1): 28-34. 
 
71. Bishop JR, Reilly JL, Harris MS, Patel SR, Kittles R, Badner JA et al. 
Pharmacogenetic associations of the type-3 metabotropic glutamate receptor 
(GRM3) gene with working memory and clinical symptom response to 
antipsychotics in first-episode schizophrenia. Psychopharmacology (Berl) 
2015; 232(1): 145-154. 
 
72. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH et al. 
Candidate-gene association analysis of response to risperidone in African-
American and white patients with schizophrenia. Pharmacogenomics J 2009; 
9(5): 311-318. 
 
73. Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, 
Giordano A et al. Cortisol and Inflammatory Biomarkers Predict Poor 
Treatment Response in First Episode Psychosis. Schizophr Bull 2015; 41(5): 
1162-1170. 
 
74. Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The 
blood-brain barrier in psychosis. The lancet Psychiatry 2017. 
 
75. Pollak TA, Beck K, Irani SR, Howes OD, David AS, McGuire PK. 
Autoantibodies to central nervous system neuronal surface antigens: 
psychiatric symptoms and psychopharmacological implications. 
Psychopharmacology (Berl) 2016; 233(9): 1605-1621. 
 
 
Table 1.  
Demographic and clinical characteristics of the sample. Site: London (L); Glostrup 
(G); Utrecht (U); DSM-IV diagnostic category: schizoaffective disorder (SA, 295.70); 
schizophrenia, undifferentiated type (SU, 295.90); schizophrenia, disorganised type 
(SD, 295.10); schizophrenia, paranoid type (SP, 295.30); schizophreniform disorder 
(SF, 295.40). Race: White (W) / Black (B) / Asian (A) / Other (O); Educational level: 
university finished / university unfinished / professional training finished / 
professional training unfinished / high school finished / high school unfinished / less 
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than high school; DP: Duration of psychosis prior to baseline assessment; AP naïve: 
number and percentage of sample antipsychotic naïve prior to study; AP Duration: 
For previously AP treated patients, the duration of treatment prior to inclusion; 
Substance use: cannabis (Ca); cocaine (Co); amphetamines (A); ecstasy (E); other 
(O). Concomitant medication: benzodiazepines (b); antidepressants (a); stimulants (s); 
mood stabilisers (m); PANSS positive and negative syndrome scale, PSP: personal 
and social performance scale. Percentage changes in PANSS scores include 
subtraction of minimum possible scores.  
 
Table 2.  
Voxel glutamate levels scaled to creatine (Glu/Cr) at baseline and after amisulpride 
administration. Values are expressed as mean ± s.d. (n). Site: London (L); Glostrup 
(G); Utrecht (U).  
 
Figure 1.  
Baseline glutamate (Glu/Cr) levels in the anterior cingulate cortex (ACC) in the 
Remission (blue triangle) and No Remission (red square) groups. At baseline, ACC 
Glu/Cr was significantly higher in patients (n=23) who were not in remission after 4 
weeks of treatment with amisulpride compared to those who were in remission (n=41) 
(F1,63 = 5.99; P = 0.02; ηp2 = 0.09). The values represent individual data scaled to the 
site mean, with the group mean indicated by the grey bar.  
 
 
Figure 2.  
Relationships between glutamate (Glu/Cr) levels in the anterior cingulate cortex 
(ACC) and symptom severity. A: ACC Glu/Cr and baseline positive and negative 
syndrome scale (PANSS) total score (n = 69; r2 = 0.08; β = 0.28; t = 2.38; P = 0.02); 
B: ACC Glu/Cr and baseline PANSS general score (n = 69; r2 = 0.09; β = 0.31; t = 
2.66; P = 0.01); C: ACC Glu/Cr and follow-up PANSS total score (n = 65; r2 = 0.09; 
β = 0.30; t = 2.49; P = 0.02); D: ACC Glu/Cr and follow-up PANSS general score (n 
= 65; r2 = 0.07; β = 0.27; t = 2.20; P = 0.03). Glu/Cr measures are centred by site 
mean. Groups are indicated as Remission (blue triangle), Non-Remission (red square) 
and remission status unknown (green cross).  
 
Figure 3.  
In both the anterior cingulate cortex (ACC) and in the thalamus, Glu/Cr was 
significantly lower at the end of 4 weeks treatment with amisulpride than at baseline; 
(ACC: F1,35 = 4.68; P = 0.04; ηp2 = 0.12; thalamus: F1,44 = 5.67; P = 0.02; ηp2 = 
0.11). In the ACC, but not in the thalamus, Glu/Cr was higher in the Non-Remission 
(red square) group than in the Remission group (blue triangle) at both baseline and at 














































































































































































































 Total patient 
group 
Baseline N=71; 
Follow-up N= 65. 
Remission
N = 41 
No Remission 
N = 24 
P value 
R vs. NR 
Age: mean ± s.d. years 24.7 ± 5.4 26.2 ± 5.9 22.3 ± 3.9 P = 0.006
Gender (n) male/ female 48/23 30/11 13/11 P = 0.12 
Site (n) L/G/U 26/31/14 17/16/8 5/13/6 P = 0.24 
DSM-IV: 
SA/SU/SD/SP/SF 
4/11/4/36/16 2/5/1/24/9 0/5/3/10/6 P = 0.21 
Ethnicity (n) W/B/A/O 50/11/7/3 25/7/7/2 20/4/0/0 P = 0.10 




P = 0.35 
DP: median (min - max)  
months 
6 (1 - 24) 5 (1 – 24) 6 (1 – 24) P = 0.35 
AP naïve: n, (%) 45 (63%) 24 (59%) 18 (75%) P = 0.11 
Previously medicated: n, 
(%) 




12/9/2/1/1/1 7/6/2/1/1/0 3/2/0/0/0/1 P = 0.50 
Previous AP duration: 
median, (min-max) days 
9 (3-14) 11 (3-14) 7 (4-8) P = 0.24 
Substance use ever Y/N 49/22 28/13 17/7 P = 0.83 
Substance use ever type 
Ca/Co/A/E/O 
45/18/14/14/15 26/10/8/8/7 5/6/4/4/7 - 
Substance use during 
study Y/N 
20/51 10/31 9/15 P = 0.22 
Substance use during 
study Ca/Co/A/E/O 
19/4/3/1/4 10/3/3/1/2 8/1/0/0/2 - 
Days to clinical follow-
up 
30.6 ± 7.6 32.1 ± 5.4 28.9 ± 9.1 P = 0.08 
Amisulpride dose at 
follow-up (mg) 
347.7 ± 138.2 307.3 ± 138.5 421.7 ± 108.5 P = 0.001
Concomitant medication 
(n) b/a/s/m 
9/14/1/1 6/9/1/0 3/5/0/1 - 
Symptoms and functioning at baseline: mean ± s.d.
PANSS Positive  20.1 ± 5.3 18.8 ± 4.6 21.7 ± 5.7 P = 0.030 
PANSS Negative  17.1 ± 6.5 15.2 ± 6.5 19.8 ± 6.0 P = 0.008 
PANSS General  36.6 ± 8.5 34.2 ± 8.2 40.7 ± 8.1 P = 0.002 
PANSS Total  73.2 ± 17.3 67.4 ± 15.7 81.9 ± 16.9 P = 0.001 
PSP 51.3 ± 12.2 52.2 ± 12.1 50.8 ± 13.1 P = 0.680 
Symptoms and functioning after amisulpride: mean ± s.d.
PANSS Positive  12.9 ± 4.7 10.8 ± 2.8 17.1 ± 4.9 P < 0.001 
PANSS Negative  14.5 ± 5.8 11.9 ± 4.1 18.7 ± 5.8 P < 0.001 
PANSS General  27.7 ± 7.7 24.8 ± 6.1 33.6 ± 7.1 P < 0.001 
PANSS Total  55.3 ± 16.2 47.5 ± 11.5 69.4 ± 14.0 P < 0.001 
PSP 61.3 ± 12.9 64.8 ± 12.8 52.6 ± 8.2 P = 0.001 
Percentage change in symptoms and functioning after amisulpride: mean ± s.d.
PANSS Positive  53.1 ± 32.3 65.9 ± 27.7 27.9 ± 25.2 P < 0.001 
PANSS Negative  9.8 ± 71.1 18.8 ± 68.4 -5.3 ± 76.0 P = 0.207 
PANSS General  43.6 ± 32.1 52.2 ± 31.8 25.3 ± 26.3 P = 0.001 
PANSS Total  42.4 ± 31.3 54.4 ± 25.4 19.5 ± 28.9 P < 0.001 
PSP -24.6 ± 36.0 -31.8 ± 37.7 -8.4 ± 26.4 P = 0.029 
Table 1.  
Demographic and clinical characteristics of the sample. Site: London (L); Glostrup 
(G); Utrecht (U); DSM-IV diagnostic category: schizoaffective disorder (SA, 295.70); 
schizophrenia, undifferentiated type (SU, 295.90); schizophrenia, disorganised type 
(SD, 295.10); schizophrenia, paranoid type (SP, 295.30); schizophreniform disorder 
(SF, 295.40). Race: White (W) / Black (B) / Asian (A) / Other (O); Educational level: 
university finished / university unfinished / professional training finished / 
professional training unfinished / high school finished / high school unfinished / less 
than high school; DP: Duration of psychosis prior to baseline assessment; AP naïve: 
number and percentage of sample antipsychotic naïve prior to study; AP Duration: 
For previously AP treated patients, the duration of treatment prior to inclusion; 
Substance use: cannabis (Ca); cocaine (Co); amphetamines (A); ecstasy (E); other 
(O). Concomitant medication: benzodiazepines (b); antidepressants (a); stimulants (s); 
mood stabilisers (m); PANSS positive and negative syndrome scale, PSP: personal 
and social performance scale. Percentage changes in PANSS scores include 




 Anterior Cingulate Cortex Left Thalamus 











L 1.33 ± 0.17 (26) 1.28 ± 0.14 (17) 1.57 ± 0.07 (5) 1.02 ± 0.13 (24) 1.00 ± 0.15 (16) 1.12 ± 0.22 (11) 
G 1.37 ± 0.17 (31) 1.35 ± 0.16 (16) 1.38 ± 0.19 (13) 1.11 ± 0.19 (27) 1.12 ± 0.15 (14) 1.12 ± 0.05 (4) 
U 1.26 ± 0.10 (13) 1.26 ± 0.11 (8) 1.26 ± 0.11 (5) 1.20 ± 0.21 (11) 1.23 ± 0.23 (8) 1.12 ± 0.14 (3) 
After amisulpride 
L 1.23 ± 0.25 (18) 1.18 ± 0.22 (14) 1.31 ± 0.32 (4) 1.02 ± 0.16 (18) 0.98 ± 0.15 (14) 1.13 ± 0.18 (4) 
G 1.32 ± 0.10 (21) 1.31 ± 0.12 (14) 1.33 ± 0.04 (7) 1.15 ± 0.20 (20) 1.12 ± 0.18 (14) 1.22 ± 0.24 (6) 
U 1.25 ± 0.19 (7) 1.20 ± 0.09 (5) 1.39 ± 0.36 (2) 1.00 ± 0.23 (7) 1.03 ± 0.27 (5) 0.93 ± 0.07 (2) 
 
Table 2.  
Voxel glutamate levels scaled to creatine (Glu/Cr) at baseline and after amisulpride 
administration. Values are expressed as mean ± s.d. (n). Site: London (L); Glostrup 
(G); Utrecht (U).  
 
